Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Responsible Information Policy

PeptideStacks publishes evidence summaries for research literacy. This page explains why that scope is deliberately narrow.

Why we avoid practical-use instructions

For many of the compounds discussed on this site there is little or no published human evidence: the studies are in cells or animals, or the human reports are small and uncontrolled. Some, such as semaglutide and tirzepatide, are named as licensed UK medicines on the MHRA’s GLP-1 medicines page (GOV.UK, page updated 5 February 2026), and the pages for them cite the label.

For that reason we do not publish “how to use” content: no injection technique, vial-to-syringe arithmetic intended for human or animal use, cycle planners, stack builders for use, or personalised dose calculations.

YMYL sensitivity

Peptides sit in the “Your Money or Your Life” (YMYL) content category. Errors in this category can cause real harm — health, financial, or legal. We hold our content to a higher standard accordingly: stronger sourcing requirements, conservative evidence grades, and explicit framing of what is and is not known.

Not medical or veterinary advice

Nothing on PeptideStacks is medical advice, diagnosis, treatment recommendation, or veterinary advice. No physician–patient relationship is created by reading this content. Readers should consult a qualified, registered healthcare professional for any health concern.

Adverse events and emergencies

If you are experiencing a medical emergency, contact your local emergency services. In the UK, that is 999 (or 111 for urgent but non-life-threatening concerns). The MHRA says that anyone can report an issue with a medicine to its Yellow Card scheme. Discuss any reaction with a clinician.

What we will not publish

  • Editorial sourcing or vendor recommendations within research content. Clearly-labelled sponsor and sister-site placement is permitted in dedicated panels, with disclosure — see our conflict-of-interest page. Sponsor placement is deliberately suppressed on POM-adjacent peptide / stack pages.
  • Importation advice.
  • Self-administration or self-injection instructions.
  • Personalised dose calculations for human or animal use.
  • Cycle planners or protocol generators framed for use.
  • Anti-doping evasion advice.
  • Claims of safety that no source supports.
  • Public-facing advertising of UK prescription-only medicines, including in any sponsor or sister-site placement.

What we do publish

  • Evidence reviews — what published studies have found, with their limitations.
  • Mechanism summaries — how a peptide is believed to act, framed appropriately.
  • Regulatory context — on every editorial page, dated statements from regulators and labels, each linked to its source, rather than our own reading of the law.
  • Safety signals — adverse events reported in literature, contamination risk, immunogenicity.
  • Misinformation flags — common marketing claims that the evidence does not support.
  • Research-literacy tools — to help readers interpret studies rather than to instruct use.

If you are considering using a peptide

Speak to a qualified clinician. Whether a medicine is suitable for you is a decision for a prescriber who knows your circumstances, not for a website. If a clinician has not approved a peptide for use in your case, we cannot fill that gap.